PMC2648641_01
MRI brain T1 with gadolinium
after stopping bevacizumab with irinotecan.
JO2008-942618.001.jpg
PMC2648641_01_JO2008-942618.001.jpg
fig1
However, after seven cycles on this regimen a brain MRI showed increased mass effect and interval development of abnormal contrast enhancement in the medial hemispheric aspect of the right occipital and parietal lobe area, compatible with progression of disease (Figure 1).
Brain T1 with gadolinium
prior to reinduction with bevacizumab with PLD.
JO2008-942618.002.jpg
PMC2648641_01_JO2008-942618.002.jpg
fig2
After 2 cycles on this regimen, his follow-up brain MRI showed  progression of disease (Figure 2).
Brain T1 with gadolinium
after treatment with bevacizumab with PLD.
JO2008-942618.003.jpg
PMC2648641_01_JO2008-942618.003.jpg
fig3
His brain MRI  (T1 with gadolinium, FLAIR and T2 weighted images) after 4 treatments showed substantial  decrease in bulk of the large mass in the right posterior cerebral hemisphere with  associated decrease in edema (Figure 3).